Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397

Citigroup analyst Yigal Nochomovitz has reiterated a Buy rating on Ligand Pharmaceuticals (NASDAQ: LGND) and increased the price target from $390 to $397. This adjustment reflects a positive outlook for the company's performance.